Should I start Mounjaro? What the clinical evidence says before you decide

What the trial results mean, and what they don't

The SURMOUNT-1 trial, published in the New England Journal of Medicine, randomised 2,539 adults with obesity but without type 2 diabetes to tirzepatide or placebo over 72 weeks. At the 15mg dose, average weight loss reached around 20–21%, with some analyses reporting reductions approaching 22.5% among participants who completed the full course. Those are meaningful numbers. They helped persuade NICE to recommend tirzepatide (TA1026) for use in the UK in December 2024.

What the headline figures don't tell you is how your individual response will look, how well you'll tolerate the early weeks, or whether your medical history makes tirzepatide a poor fit. Trial participants are selected; you are not a trial average. The evidence makes a strong case for tirzepatide as a treatment class. It doesn't make the decision for you.

It's also worth knowing that SURMOUNT-1 participants followed a reduced-calorie diet and increased physical activity alongside the medicine. The trial was designed that way because the medicine works best as part of a broader shift, not as a standalone fix. If you want to read more about how the drug itself works before deciding, the tirzepatide overview on this site covers the mechanism in plain language.

Who the clinical guidance says is a reasonable candidate

The licensed criteria for Mounjaro in the UK cover adults with a BMI of 30 or above, or 27 or above alongside at least one weight-related health condition, for example hypertension, type 2 diabetes, high cholesterol, or obstructive sleep apnoea. NICE's recommendation sets a higher bar for NHS access: a BMI of 35 or above with at least one qualifying comorbidity. For some ethnic backgrounds, those thresholds are reduced by 2.5 kg/m² under UK guidance, so the numbers aren't universal. You can use the NHS BMI calculator to find your starting point.

BMI alone, though, has never been the full story. Prescribers also consider your cardiovascular history, kidney and liver function, any personal or family history of medullary thyroid carcinoma or a condition called MEN2, and whether you're planning a pregnancy or currently breastfeeding. Mounjaro isn't licensed for use in pregnancy or while breastfeeding, and it's not licensed for anyone under 18. A good prescriber doesn't just tick the BMI box; they look at the whole picture. If you're weighing up your options more broadly, the weight-loss treatment overview on this site compares the licensed choices available in the UK.

Side effects to know before you commit

Most people who experience side effects with Mounjaro notice them in the first few weeks of treatment or after a dose increase. The pattern is predominantly gastrointestinal: nausea, constipation, loose stools, indigestion, and sometimes burping or reflux. For many people these settle within a week or two as the body adjusts. Keeping the pen in the fridge door alongside everyday items is a small routine detail, but having it visible makes it genuinely easier to remember your weekly injection and stay consistent through the early adjustment phase.

Rarer but more serious effects exist and are worth understanding before you start. Acute pancreatitis is a known, infrequent but potentially serious risk, the MHRA highlighted this in a Drug Safety Update in January 2026. Severe, persistent stomach pain that radiates to the back, with or without vomiting, warrants urgent medical attention. Gallbladder problems, allergic reactions, and dehydration from prolonged GI illness are also flagged in the prescribing information. The NHS medicines page for tirzepatide lists all recognised side effects and explains what to do if they occur. Reading it before your first injection is time well spent.

If you're on an oral contraceptive, note that tirzepatide may temporarily reduce pill absorption. UK guidance recommends adding a non-oral method for the first four weeks of treatment and for four weeks after each dose increase. Your prescriber will cover this, but it's useful to know before the conversation.

The practical question: how do you actually start?

Mounjaro is a prescription-only medicine. The only lawful route to it in the UK is a genuine clinical assessment followed by a prescription from a qualified prescriber. That assessment exists to catch contraindications, check your current medicines for interactions, and confirm that treatment is appropriate for you, it's not a formality to work around. If you're thinking about cost as part of the decision, it helps to understand what's included in private prescriptions across providers, and what often isn't; the context behind Mounjaro's UK pricing explains the landscape clearly.

At nume, every consultation is reviewed the same day by a GPhC-registered Independent Prescriber, a real clinician, not an automated filter. If approved as clinically suitable, your first pen is dispatched the same day (for orders placed before noon, Monday to Friday) and arrives the next working day by tracked DPD in plain packaging. There are no subscriptions and no hidden costs. If you're still working out whether Mounjaro is the right treatment for you, that guide walks through the key considerations in plain language. If you've been on Mounjaro elsewhere and are thinking about switching, the reorder process page explains what's involved. And if you'd like to talk through whether now is the right time to take Mounjaro, including where you are in your health journey, that page covers the practical side of timing and readiness. If you're still weighing up whether going on Mounjaro is the right move for you personally, the clinical team is there for exactly that. The decision is yours. Start your free consultation when you're ready to get a proper clinical view.